

Supporting Information

Zheng *et al.* 10.1073/pnas.0802253105




Fig. S1. Immunoblotting image of tMOR localization. (A) Sucrose gradient fractionation of the cell homogenates. Immunoblotting image for Fig. 1 A. HEK293 cells were treated with 1 μ M morphine, 10 nM etorphine, or 10 nM etorphine with 0.4 M sucrose pretreatment for 10 min (Etorphine+S). Then MOR location on the cell membrane was determined, as described in *Materials and Methods*. G α q represented the location of lipid raft domains, while transferin receptor (TR) showed nonraft domains. (B) Distribution of MOR after M β CD and cholesterol treatment. Immunoblotting image for Fig. 2. HEK293 were treated with 1 mM M β CD for 1 h (M β CD) or 1 mM M β CD for 1 h and then 10 μ g/ml cholesterol for 3 h (M β CD+Chol). Immunoreactivities of G α i2, G α q, and TR were also detected.




Fig. S2. MOR used $G\alpha i2$ to mediate ERK1/2 phosphorylation. N2A cells with MOR-HA stably expressed were infected with different PTX-insensitive $G\alpha$, control (A), $G\alpha o$ (B), $G\alpha i2$ (C), and $G\alpha i3$ (D). Before experiments, 100 ng/ml PTX was used to treat the cells overnight. Then the cells were exposed to 1 μ M morphine or 10 nM etorphine for 10 min. The bar graphs represent the averages of ERK1/2 phosphorylation increases from the basal level determined in experiments repeated at least three times. *, $P \leq 0.05$ and **, $P \leq 0.005$ in two-tail t test.




Fig. S3. MOR translocation in a mutant lacking GRK phosphorylation sites. HEK293 cells transfected with MOR363D were treated either with 1 μ M morphine (10 min) or with 10 nM etorphine (10 min or 3 h). The locations of MOR in the sucrose gradient fractions were then determined. All of the experiments were repeated at least three times. *, $P \leq 0.05$ and **, $P \leq 0.005$ in two-tail t test.

